Navigation Links
Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis
Date:7/7/2011

everal countries(1,5). The extension phase of the Phase II study, which is also being presented at the conference, provides data to support the treatment of patients with SEGA associated with TSC for a duration of up to three years(5).

Regulatory approvals for everolimus have been granted for this patient population as Afinitor in the United States, Canada, Brazil, Guatemala, the Philippines, Columbia and Korea, and as Votubia® in Switzerland. In June, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for the approval of everolimus for this use in the European Union (EU).

About the EXIST-1 Phase III trialEXIST-1 is a Phase III randomized, placebo-controlled, double-blind, parallel group, international, multicenter study examining the efficacy and safety of everolimus versus placebo for the treatment of patients with SEGA associated with TSC. Trial patients (median age=9.46, range 0.8-26.6) were randomized to receive either everolimus (n=78) or placebo (n=39) at a daily starting dose of 4.5 mg/m2. By the cut-off date of March 2, 2011, the median treatment duration was 9.6 months (range 5.5-18.1 months) in the everolimus arm and 8.3 months (range 3.2-18.3 months) in the placebo arm. The trial met the primary endpoint of overall SEGA response rate versus placebo(1).

Three key secondary endpoints were also assessed: change in seizure frequency, time to SEGA progression and skin lesion response rate. The analysis of the first secondary endpoint, the change in seizure frequency, was inconclusive. This may have been due to the method of assessment (single 24-hour video electroencephalograms, or EEGs) and a very limited number of patients with evaluable seizures at study entry. In this trial, the impact on seizure frequency was not demonstrated. Another study specifically designed to examine the efficacy of everolimus on seizure response in patients with TSC as the primary endpoint is ongoing(1).

Given
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine technology :

1. Ampio Pharmaceuticals Announces Treatment of First Patient in Phase 1b Ampion-In -Knee (AIK) Trial for Osteoarthritis in Australia
2. GlaxoSmithKline Implements Next Phase of New Incentive Compensation Program for U.S. Sales Representatives
3. Ataluren Phase 2 Data in Nonsense Mutation Cystic Fibrosis Published in the European Respiratory Journal
4. Endo Announces Topline Results From Phase 2 Study of Axomadol in Chronic Low Back Pain
5. Phase III Study Shows Once-Daily NVA237 is Superior to Placebo and Similar to Tiotropium in Improving Lung Function in COPD
6. DNA Medicine Institute Awarded Two Phase III SBIR NASA Contracts for Its rHEALTH Sensor
7. Phase I of the Swedish/Issaquah Medical Center Campus to Open in July
8. The Lancet Publishes Data from Protege, MacroGenics Phase 3 Clinical Study of Teplizumab in Type 1 Diabetes Patients
9. Morphotek®, Inc. Announces Initiation of Farletuzumab Phase II Study in First-Line Treatment of Non-Small Cell Lung Cancer
10. Palatin Technologies, Inc. Initiates Enrollment in Phase 2b Trial With Bremelanotide in Women With Female Sexual Dysfunction
11. Cardium Announces Plans to Acquire Transdel Pharmaceuticals Phase 3 Topical Analgesic and Cosmeceutical Business Assets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... COLUMBUS, Ohio , Aug. 19, 2014 ... Ohio medical device company, announced today that ... FloShield laparoscopic and robotic visualization system in ... approved for sale in Japan ... Corporation is also the exclusive distributor for Karl Storz ...
(Date:8/19/2014)... DUBLIN , Aug. 19, 2014 Research ... "Human Growth Hormone Drugs - Global Strategic Business Report" ... the worldwide markets for Human Growth Hormone Drugs in US$ ... and Others. The report provides separate comprehensive analytics ... Japan , Europe , ...
(Date:8/19/2014)... -- According to Kalorama Information, electronic medical records (EMR) ... in healthcare a reality, and this a factor that ... Recovery and Reinvestment Act, the U.S. government dedicated $20.6 ... will start applying soon for use of paper records.  ... of the EMR industry, EMR 2014: The Market ...
Breaking Medicine Technology:Minimally Invasive Devices and Mitsubishi Medical Japan Forge Exclusive Distribution Agreement 2Global Human Growth Hormone Drugs - Strategic Business Report 2014 2Kalorama: EMR Paves the Way for Big Data 2Kalorama: EMR Paves the Way for Big Data 3
... ANGELES, Jan. 13, 2011 UBM Canon and ... webinar to its webcast series on The Fundamentals of ... on Advanced Assay Technologies and Development Methods ... experts in the industry.   (Logo:   ...
... 13, 2011 CareGiver remote instrument support has expanded ... Medical System, Inc. ("VMSI") is the leading innovator in ... 5 years of success on the SYMPHONY H&E slide ... BenchMark ULTRA, strengthening the integration of the SYMPHONY and ...
Cached Medicine Technology:Advanced Assay Technologies and Development Methods 2CareGiver, Ventana Medical Systems, Inc. Remote Instrument Support, Has Expanded to Include the Ventana BenchMark ULTRA Automated Stainer 2CareGiver, Ventana Medical Systems, Inc. Remote Instrument Support, Has Expanded to Include the Ventana BenchMark ULTRA Automated Stainer 3
(Date:8/20/2014)... August 20, 2014 It’s no secret ... According to the National Institute on Drug Abuse, nearly ... drugs. What’s even more alarming is the fact that ... last decade. , Those locked in a struggle with ... way out. But now, the newly-redesigned AbuseTreatmentCenters.net has released ...
(Date:8/20/2014)... 20, 2014 One Call Alert expands its ... of ResCube, a fully-mobile wearable device that connects customers to ... button, 24 hours a day, 365 days a year. , ... cross country. It operates on the T-Mobile nationwide network like ... in to work. , Like with the other One Call ...
(Date:8/20/2014)... at the Universities of Manchester and Auckland suggest that both ... mechanism. , The findings, published today in the ... or type-1 diabetes and type-2 diabetes are both caused by ... , The results, based on 20 years, work ... both be slowed down and potentially reversed by medicines that ...
(Date:8/20/2014)... Fresh from the cradle of a world-class running city, an ... , Urbini, a new collection of versatile baby gear from ... jogger to its lineup. , The Avi has been in ... the latest racing styles and a set of features to ... a swift, smooth ride on runs, power-walks and causal strolls. ...
(Date:8/20/2014)... 20, 2014 Today, Zane Benefits, the ... open enrollment for 2015. , According to Zane Benefits, ... in November, employees are encouraged to start thinking about ... 2015, the open enrollment period will run from November ... 2015 individuals can purchase a new individual health insurance ...
Breaking Medicine News(10 mins):Health News:Re-Launched AbuseTreatmentCenters.net Offering New List of Substance Abuse Resources 2Health News:One Call Alert Introduces ResCube™, Smallest Mobile Medical Alert System on Market 2Health News:One Call Alert Introduces ResCube™, Smallest Mobile Medical Alert System on Market 3Health News:Scientists show type-1 and type-2 diabetes are caused by same underlying mechanism 2Health News:Urbini Breezes Through Summer with New Jogging Stroller 2
... , , WESTBURY, N.Y., July ... in the Ophthalmic Consultants of Long Island (OCLI) practice will perform ... of sight to those who have lost some or all of ... Cataract USA program, is offering this outpatient surgical procedure to residents ...
... , , , HOUSTON, ... , , If you would like to learn ... Texas Health Institute as they host a morning-long forum on "Building a Federal ... The event will be held at St. Joseph Medical Center, 1401 St. ...
... NxStage Medical, Inc. (Nasdaq: NXTM ), a leading ... financial results for the second quarter ended June 30, 2009 on ... , , NxStage will also host ... 5, 2009 to discuss its second quarter financial results. To listen ...
... , , WALTHAM, Mass., ... and advisory firms focusing on pharmaceutical and healthcare issues, finds that ... million in 2008 to more than $315 million in 2013. The ... Humira and Schering-Plough,s Remicade which recorded sales of $50 million and ...
... , , BANNOCKBURN, Ill., July ... in the United States(1). Yet it,s often not until the untimely passing ... or Tim Russert - that the issue is brought to the forefront ... heightened focus on heart health, a recent survey(2) uncovered that only 14 ...
... on intelligence tests at age 5 , MONDAY, July ... of a common airborne pollutant compound seems to threaten ... , The finding is based on the experience of ... City area. Specifically, it indicates that high prenatal exposure ...
Cached Medicine News:Health News:Ophthalmic Consultants of Long Island (OCLI), the Largest and One of the Most Prestigious Multi-Specialty Ophthalmology Practices on Long Island, Participates in Mission Cataract USA 2Health News:Ophthalmic Consultants of Long Island (OCLI), the Largest and One of the Most Prestigious Multi-Specialty Ophthalmology Practices on Long Island, Participates in Mission Cataract USA 3Health News:Building a Federal Health Board - Impact on Texas 2Health News:NxStage to Report Second Quarter 2009 Financial Results 2Health News:Brazil's Rheumatoid Arthritis Drug Market Will Grow $115 Million by 2013 2Health News:Need for At-Home Blood Pressure Monitoring Underscored by High-Profile Cardiac Deaths 2Health News:Need for At-Home Blood Pressure Monitoring Underscored by High-Profile Cardiac Deaths 3Health News:Exposure to Common Pollutant in Womb Might Lower IQ 2Health News:Exposure to Common Pollutant in Womb Might Lower IQ 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: